Probiotics & Synbiotics CDMO Services at MycoVista are built on one simple conviction: these aren’t supplements—they’re living systems that demand the same rigor as any biologic drug. Probiotics are not powders with wishful CFUs; they are living therapeutic entities governed by physics, ecology, and regulatory logic. Synbiotics are not marketing fusions but engineered partnerships—precision-matched combinations of microbial life and selective substrates, designed to deliver measurable clinical and metabolic outcomes.

At MycoVista, Probiotics & Synbiotics CDMO Services operate under the same disciplined spine that defines every modality we run: QTPP → CQAs → CPPs mapped up front, guardbands established through focused DoE, and analytics chosen because they measure truth, not optimism. Every project is executed with precision.

We treat every live biotherapeutic or synbiotic formulation as a high-consequence system—whether it’s a clinical-stage Live Biotherapeutic Product (LBP), a precision dietary supplement, a veterinary probiotic, or an advanced synbiotic integrating pre-, pro-, and postbiotic components. Each program begins with manufacturability as the default outcome: growth, harvest, stabilization, and packaging designed as one continuous control strategy.

This is what distinguishes MycoVista: we merge survival biology with manufacturable design. Our Probiotics & Synbiotics CDMO Services quantify the environmental physics that govern microbial survival—acid and bile transit, oxygen and moisture exposure, glass transition (T_g), and water activity (a_w)—and build those parameters directly into batch logic with alarms and interlocks. We don’t hope CFUs survive; we engineer the physics that make survival predictable.

You’ll find the familiar rhythm of our organization here: Design → Data → Decision → GMP. It’s the same backbone that has carried recombinant proteins, mRNA, enzymes, and biologics to inspection-grade outcomes—now applied to the world of living microbe-based therapeutics. The result is simple and measurable: lots that behave, dossiers that defend, and products that survive manufacturing, storage, shipping, and the gastrointestinal journey to do what they were designed for.

At MycoVista, Probiotics & Synbiotics CDMO Services mean more than formulation—they mean confidence. Every protocol, every guardband, every validation is tied to data integrity and reproducibility. We ensure that your probiotic survives not just the centrifuge and the lyophilizer, but the scrutiny of regulators and reviewers. That’s why our programs scale cleanly from pilot to GMP, passing every gate along the way—with no detours, no broken handoffs, and no surprises when the inspector walks in.

Why teams choose MycoVista for Probiotics & Synbiotics

• Manufacturability by default. Growth → harvest → stabilization → formulation → packaging tuned as one control strategy. We don’t “win” CFUs at the expense of filterability, fill weight variability, or stability-on-paper.
• Survival physics, not folklore. Acid/bile transit, oxygen/moisture exposure, water activity (a_w), glass transition (T_g), and headspace management are engineered and measured—then written into batch logic with interlocks.
• True synbiotic design. We prove substrate preference, dose-response, and interference risk in development; we pre-specify comparability rules so future substrate or excipient changes remain file-able.
• Digital QMS (ALCOA+). LIMS/ELN + eBMR/eBR + validated CDS; mirrored SOPs and method versions across both hubs; review-by-exception that keeps QA focused on deltas.
• Operator-holdable ranges. NOR/PAR backed by edge-of-failure exercises; alarms prevent heroics; CPV dashboards make drift obvious.
• Regulatory fluency. Dietary supplement dossiers that actually stand up; IND/IMPD text that mirrors the plant; PAI playbooks included for LBPs.

QbD, for real (how we architect your program)

We start where it ends: dose and dossier. Together we define the QTPP (dose form, CFU at release, CFU at shelf-life, species/strain identity, resistance profile, contaminants, excipient/substrate pairing, packaging, storage conditions, shipping profile, target markets and claims). That becomes a defendable CQA set (identity, purity, potency/CFU trajectory, viability under stress, moisture, oxygen, residual solvents, contaminants—including phage/antibiotic carryover—and sensory where relevant). From there we lock CPPs/CMAs: media composition, pH/DO profiles, growth temperature, harvest timing, cryo/lyo protectants, drying kinetics, blend homogeneity, fill weight control, coating thickness, headspace oxygen, desiccant spec, seal integrity.

Focused DoE quantifies effects (e.g., protectant ratio × shelf moisture × T_g on 6-, 12-, 24-month CFU retention). Edge-of-failure establishes the guardbands we’ll actually run: exposure to 40–60% RH pulses, transit heat spikes, agitation/impact. The resulting control strategy is embedded into eBMR/eBR with limits, alarms, and investigation trees. No slideware.

Upstream development (grow what survives)

• Strain verification & provenance. Reference genomes on file; identity by WGS or validated rapid ID; antibiotic resistance profiling where required; deposit or master cell bank built under qualified conditions.
• Media & process screens. Carbon/nitrogen sources, buffer capacity, growth factors, oxygen tolerance; spore-formers tuned for sporulation efficiency vs. undesirable metabolites; non-spore-formers tuned for cell membrane robustness.
• Bioreactor control. pH/DO cascades, carbon feed where justified, anti-foam governance, k_La mapping. For sensitive anaerobes/facultatives, dissolved oxygen envelopes are set with fail-safes.
• Harvest definition. Growth-phase vs. stationary-phase targeting, stress-conditioning for downstream resilience (where data support it). Mixing and shear envelopes protect viability.

What you get: a strain + recipe that scales, harvest windows with headroom, and mass-balance you can audit.

Downstream & stabilization

• Clarification & concentration. Gentle centrifugation or TFF, shear envelopes instrumented; conductivity and pH hold points; wash buffers engineered for downstream protectants.
• Protectants & cryo/lyo design. Trehalose, sucrose, skim milk, amino-acid blends, proteins/polymers as justified by data; ratios tuned via DoE to maximize CFU retention through freeze–thaw and drying.
• Lyophilization. Collapse temperature determinations, primary/secondary drying ramps, chamber pressure control; cycle design to target residual moisture windows that balance viability vs. shelf stability. Shelf mapping and thermal probes by lot; load patterns validated.
• Spray drying (where appropriate). Inlet/outlet temperatures, atomization energy, feed solids, and protectants tuned to keep viability in family; cyclone/collector losses quantified; a_w and T_g targeted to protect through shipping.
• Microencapsulation & coatings. Alginate, lipid, or polymer shells; enteric or oxygen/moisture barrier coatings; coating thickness and release profiles verified (acid/bile challenge).
• Granulation & blending. High-shear or fluid-bed routes for blend homogeneity; RSD targets locked; sequencing controls to avoid moisture pick-up and segregation.
• Fill–finish. Stick packers, sachet systems, capsule fillers, and bottling lines with RH and temperature governance; headspace oxygen limits with nitrogen flushing; desiccant spec embedded; torque/seal verification and CCIT (where applicable).
• Packaging & labeling. Barrier films, blister or bottle; ink/adhesive compatibility; serialization/traceability where required.

What you get: a stabilized intermediate and final DP that survive manufacturing, sit on a real shelf, ride in a real truck, and still meet label claim.

Synbiotic engineering

• Substrate matching. We quantify growth preference curves for the target strain(s) across candidate fibers/sugars; dose × time × CFU models predict competitive fitness in the presence of typical diet backgrounds.
• Interference mapping. We test for antagonism with co-formulated strains or excipients; we prespecify equivalence windows so future excipient or substrate changes run through a predictable comparability plan.
• Release & transit design. Coatings and microencapsulation tuned to GI release; acid/bile challenge protocols mimic stomach/duodenum conditions, not wishful buffers.
• Postbiotics & adjuncts. When using defined metabolites or phage adjuncts, containment and cleaning validation match the chemistry/biology—MACO/PDE calculations documented.

Analytics

Identity & purity

• WGS (where required), MALDI-TOF or validated species/strain ID assays; contaminant panels (yeast/mold, coliforms, E. coli, Salmonella, Staph aureus), bacteriophage screens for sensitive programs, residual antibiotics, and allergen carryover where relevant.

Potency & viability

• CFU by validated plating or MPN; flow cytometry viability (for orthogonal read); accelerated/cycling stress CFU projections; survivability-in-matrix assays for finished DP. For spores: spore counts vs. vegetative cells tracked.

Chemistry & stability

• Moisture (LOD/KF), water activity (a_w), T_g/T_m (DSC), oxygen in headspace, residual solvents, protectant assay (where justified).
• Regression-based shelf life with confidence bounds; in-use and shipping simulations that mirror your lanes; time-out-of-refrigeration rules written into SOPs.

Performance

• Acid/bile challenge; disintegration and dissolution for coated forms; content uniformity; blend homogeneity; dusting and particle size distributions for VFFS behavior.

Data integrity

• System suitability predicts bad days; orthogonal confirmations where they reduce risk; eBMR/eBR + LIMS trending; CPV dashboards across hubs.

Validation & qualification

• Method lifecycle: development → transfer → qualification/validation sized to decision phase (ICH Q2(R2)/Q14 principles where applicable).
• Process validation: Stage 1 knowledge in the file, Stage 2 PPQ lots sized by complexity/risk (often three) with boundary/worst-case confirmation before report.
• Holds & cleaning: microbiological hold-time studies; cleaning validation with MACO/PDE and product contact matrices; segregation and line clearances defined.
• Aseptic pathways: media fills where liquid DP is justified; environmental monitoring plans with continuous non-viable + qualified viable routes; filter integrity baked into eBMR.

Regulatory & documentation

• Dietary supplement & food lanes: Part 111/117-aligned batch logic, supplier qualification, raw-material COAs/specs, complaint/recall readiness, label-claim substantiation with stability and CFU decay models.
• LBP (drug) lanes: IND/IMPD authoring (Modules 2/3), comparability protocols, container-closure & CCIT where applicable, clinical supply labeling and accountability, PAI walk-routes and trace tables that map equipment, training, EM/utilities, and CPV.
• Change control: prespecified comparability with equivalence windows for site/scale/excipient changes; orthogonal confirmations for high-impact attributes; lifecycle management in eCTD sequences.

Facilities & scale

• Upstream: bench and pilot through stainless trains; anaerobe-capable rigs; spore-former containment where required; PAT hooks for pH/DO/OUR and biomass proxies.
• Stabilization: GMP lyophilizers with shelf mapping and validated cycles; spray dryers with inlet/outlet control and cyclone loss trending; fluid-bed granulation; blending suites with humidity governance.
• Fill–finish: VFFS stick packers, sachet and bottling lines, capsule fillers; headspace management (nitrogen) and desiccant controls; torque/seal/CCIT as appropriate.
• Controlled environments: ISO 8/7 cleanrooms, positive cascades, unidirectional flows; validated HPW/clean steam/compressed air; continuous EM trending; BSL-2 where required.
• Digital spine: validated CDS + LIMS/ELN + eBMR/eBR; mirrored San Diego ↔ Montréal.

Program Onboarding (first 30 days)

Day 0–5 — Control Strategy Stub
QTPP drafted; CQAs ranked; candidate CPPs and acceptance criteria proposed; analytical plan skeleton (identity, purity, potency, a_w, T_g, acid/bile, contaminants).

Day 6–15 — DoE & Validation Plan
Focused DoE on protectants × moisture × aging; upstream growth/harvest levers; lyo or spray-dry cycle design space; method qualification/validation plan sized to lane (dietary vs. LBP). If liquid DP, media-fill strategy and EM plan outlined.

Day 16–30 — Digital Scaffolding & Calendar
eBMR recipes with NOR/PAR/interlocks; LIMS templates; EM/utilities hooks; Gantt + FMEA with decision gates to label claim and shelf-life lock; comparability skeleton pre-filed.

Deliverable: Signed, inspection-grade 30-day package (control strategy, DoE/validation/stability plans, comparability outline, calendar).

Deliverables

1. Control Strategy (QTPP → CQAs → CPPs) with acceptance criteria, IPCs, alarms/interlocks, investigation trees.
2. Process Description that mirrors the floor—NOR/PAR and edge-of-failure guardbands written into eBMR/eBR.
3. Analytics Package: method URS → development → transfer → qualification/validation, system suitability, orthogonal confirmations, trending and drift analysis.
4. Validation Dossier: lyophilization/spray-dry cycles, holds, cleaning, (where applicable) media fills, and PPQ protocols sized to risk.
5. Stability Protocols & Reports: real/accelerated/in-use/transport, regression-based shelf life with confidence bounds, time-out-of-refrigeration rules.
6. Comparability: prespecified protocols for site/scale/excipient/substrate changes, with equivalence windows and orthogonal checks.
7. Regulatory Text: Part 111/117 packages or IND/IMPD/BLA CMC ready to file; PAI playbooks and floor routes included.
8. CPV Dashboards: cross-site control charts for CFU decay, a_w, moisture, oxygen, complaint signals, and process KPIs—San Diego ↔ Montréal by default.

Example solution paths

A) Spore-forming Bacillus stick packs (dietary)
Goal: 50B CFU/serving, 24-month shelf at ≤25 °C, high-humidity markets.
Approach: spore yield maximization, low-shear concentration, protectant blend tuned for a_w < 0.25, nitrogen headspace, desiccant map by bottle size, 40 °C/75% RH excursions validated.

Outcome: CFU trajectory within prediction band; claims defended with regression; packaging SOPs lock seal integrity.

B) Non-spore Lactobacillus consortium (LBP, Phase I)
Goal: 10B CFU/capsule, cold chain, enteric release, IND.
Approach: WGS identity, mixed-culture interference DoE, lyo cycle tailored to T_g, enteric coat with acid/bile pass-through proof, aseptic capsule fill in controlled RH, media fills for liquid comparator arm.

Outcome: IND filed with method lifecycle, hold-time data, and comparability plan for excipient change.

C) Synbiotic with HMO substrate (medical food route)
Goal: daily sachet; substrate-matched growth advantage; room-temperature storage.
Approach: growth preference curves, dose-matching model, spray-dried microencapsulation, sachet RH governance, human-factors checks for in-use exposure.
Outcome: label claim + “open/close” in-use rules proven; supplier qualification and variability controls pre-baked.

Probiotics & Synbiotics CDMO – FAQs

1. Do you guarantee label claim at end-of-shelf?
We guarantee control, not superstition. Shelf-life projections are regression-based with statistical confidence intervals, anchored by validated moisture (LOD/KF), oxygen ingress, and a_w (water activity) limits. Packaging is engineered as part of the control strategy—seal integrity, desiccant mass balance, and headspace gas composition are monitored by lot. Label claim then becomes a regulatory decision made from predictive data, not retrospective hope.

2. Lyophilization or spray drying?
We let the thermodynamics decide. Each strain undergoes comparative CFU-survival modeling under both freeze-dry and convective-dry conditions. Input parameters include T_g, collapse temperature, and protectant ratio, while outputs include residual moisture, viability decay slope, and process yield. The selected route is the one that closes the mass balance, meets target Enc%/a_w, and can run continuously at 3 a.m. without bricking your stability curve.

3. How do you handle multi-strain or consortium blends?
Each strain is fingerprinted by WGS or validated species/strain ID, and relative abundance is tracked via quantitative plate count or molecular barcoding. We execute antagonism and interference assays in the actual excipient matrix, not saline fantasies. Blend sequencing and RH governance live in the eBMR; blend uniformity, segregation risk, and stability are modeled and trended. Comparability protocols predefine equivalence windows for excipient, substrate, or carrier updates—so future changes remain file-able, not improvisational.

4. Can you run strict anaerobes or microaerophiles?
Yes—under conditions proven by partial-pressure mapping. Dedicated anaerobic bioreactors use oxygen-impermeable seals, pre-reduced media, nitrogen/CO₂ sparging, and scavenger systems to maintain redox potential. Sampling ports are validated for transient ingress, and dissolved oxygen profiles are instrumented. We only accept scope when full process control and headroom are demonstrable.

5. What’s your phage-control strategy?
We treat phage like a process impurity—quantified and controlled. For sensitive hosts, phage screening (PFU assays, qPCR panels) is embedded into raw-material and environmental monitoring. Cleaning validation includes virucidal agents and surface-recovery verification (log reduction ≥ 4). Line clearance and segregation are documented in the eBMR with MACO/PDE justifications specific to microbial biology.

6. How many PPQ lots do you require?
Three, typically—but justified by Stage-1 knowledge maturity and unit-operation complexity. Sampling plans use stratified statistical designs; boundary and worst-case conditions are executed pre-PPQ. We demonstrate process capability (Cp/Cpk) on CFU retention, moisture, a_w, and oxygen ingress before final report issuance, ensuring commercial predictability.

7. How is viability trended over time?
We apply Arrhenius-based kinetic modeling to accelerated and real-time stability data, establishing decay constants (k) for CFU loss. This model feeds a regression-based shelf-life projection with 95 % confidence bounds. Ongoing CPV dashboards track drift per lot and trigger deviation workflows if slopes deviate beyond ± 2 σ.

8. How do you validate acid and bile tolerance?
Each strain or consortium is subjected to standardized simulated gastric and intestinal fluid (SGF/SIF) challenges, with bile-salt profiles matching physiologic concentrations. Time-kill kinetics and log-reduction curves are compared pre- and post-formulation to quantify protection efficacy of coatings or encapsulants.

9. What governs your water-activity specifications?
a_w targets (typically ≤ 0.25 for spores; ≤ 0.20 for vegetatives) are defined from viability regression slopes and T_g thresholds. Moisture equilibration studies determine packaging equilibrium RH, ensuring CFU retention under ICH stability zones. a_w monitors are calibrated traceably, and acceptance ranges are enforced by alarm in eBMR.

10. How is oxygen ingress controlled post-fill?
We design packaging headspace to specific O₂ ppm targets, validated by inline gas analyzers. For bottles, we qualify torque, liner compression, and desiccant consumption curves; for stick packs and blisters, we validate barrier film permeability and sealing energy. CPV tracks oxygen rise rate versus predicted model.

11. Can you accommodate HMOs or complex substrates in synbiotics?
Yes—our substrate matching DoE models microbial growth rate and metabolite output across candidate oligosaccharides (e.g., GOS, XOS, HMOs). Compatibility screens include Maillard-reaction risk, pH shift, and hygroscopic interactions, ensuring stability and activity coexist.

12. How do you ensure microencapsulation performance?
We validate encapsulation efficiency and release profiles by acid-bile challenge, confocal microscopy, and dissolution assays. Coating thickness distribution is mapped via particle image analysis; variance < 10 % RSD is required. For polymeric shells, residual solvent and crosslinker content are monitored by GC and LC-MS.

13. What’s your approach to endotoxin and residual control?
Even for dietary or veterinary lanes, endotoxin is trended. We apply LAL or recombinant Factor C assays to intermediates and final DP, with acceptance limits aligned to route of administration. Residual solvents and protectants are quantified per ICH Q3C.

14. Do you perform hold-time studies?
Yes—microbiological hold-time validations define acceptable duration for intermediates pre- and post-lyophilization. Viability, CFU trajectory, and moisture profiles are compared across hold durations; acceptance ≤ 0.5 log deviation from baseline.

15. How do you qualify desiccants and headspace gas?
Desiccants are mass-balanced to equilibrium RH, with uptake kinetics curves verified at ICH 25/60 and 40/75. Nitrogen or argon headspace gases are qualified to USP <1247> purity and monitored for O₂ pickup during storage.

16. What analytical methods define identity and purity?
Strain identity by WGS, MALDI-TOF, or species-specific qPCR; purity by microbial limits and phage screen panels. For mixed consortia, we employ qPCR abundance ratios and in silico contamination filters validated by orthogonal culture.

17. Can you support regulatory filings for Live Biotherapeutic Products (LBP)?
Absolutely. IND/IMPD authoring (Modules 2/3) aligns with CBER/EMA LBP expectations—covering strain provenance, resistance profiles, genome annotation, process validation, stability modeling, and risk assessments. PAI playbooks included.

18. How are process deviations managed?
All data live in our digital QMS (ALCOA+) with automated deviation capture. Root-cause analysis uses 5-Why and FMEA linkage; CAPA closure is trended via CPV dashboards. Review-by-exception ensures QA attention stays on deltas.

19. How do you manage comparability after scale or substrate change?
We execute pre-filed comparability protocols defining acceptance windows for CFU, a_w, O₂ ingress, and acid/bile tolerance. Orthogonal confirmation includes side-by-side stability regression and equivalence testing (TOST 90 % CI).

20. How fast to “first lot that behaves”?
Stabilization programs reach first compliant lot within 6–8 weeks for reformulations, or 10–14 weeks for new builds—governed by 30-day onboarding (QTPP → CQAs → CPPs, DoE, and digital scaffolding). Biology sets the pace; we engineer everything else.

Comparability

Site, scale, excipient, substrate, or packaging changes follow prespecified protocols: acceptance windows, bias/precision checks, and orthogonal confirmations for high-impact attributes (e.g., CFU trajectory, a_w, oxygen ingress, acid/bile response). Changes become predictable and file-able, not improvisational.

How we work (end-to-end flow)

1. Survey & CDA → IP protected, scope locked.
2. Technical deep-dive → CQAs, risks, constraints agreed.
3. Proposal → scope, cost, timelines; iterate until right.
4. (Optional) QA audit → full transparency.
5. Onboarding (0–30 days) → control strategy stub; DoE/validation plans; digital scaffolding; calendar.
6. Design → Data → run the plan; publish weekly variance reports; hold gates.
7. Decision → advance only when lots behave and the file defends; otherwise redesign, then lock.

What makes MycoVista different

What makes MycoVista different starts on the floor, not in a slide deck. We work Design → Data → Decision—no detours. Before PPQ, you see hard guardbands and the edge-of-failure so the team knows the true operating window. We build an operator-holdable reality: interlocks that stop hero moves, recipes with headroom instead of red-line settings, and a steady rhythm—stabilize, optimize, then lock it down. Docs are kept current as we go, so inspectors don’t surprise anyone and your crew isn’t chasing binders.

Innovation, for us, is useful or it’s out. We’ll bring enteric coatings, encapsulation, micro-aerophilic rigs, or continuous operations only when validation and operations can actually carry them end-to-end. Specs and claims come from real data distributions and clinical context—not wishful targets. When audit day lands, we stand there with you. That’s what makes MycoVista different: manufacturability by default, choices grounded in data, and processes your operators can run on a Tuesday without drama.

Email our team directly at info@mycovistabiotech.com

Learn more about our –> Animal Health CDMO Services